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ABSTRACT: Background. Tumor regression after induction chemotherapy
(ICT) identifies laryngeal cancers that are responsive to chemoradiation.
Patient immune parameters have recently been associated with response to
chemotherapy and may identify responding patients. A retrospective analysis
was performed to determine if pretreatment, circulating T lymphocyte levels
predicted ICT response in patients with advanced laryngeal cancer.
Methods. Pretreatment, circulating T lymphocyte subpopulations were
correlated with response to therapy and survival. Results were compared
with similar data from an identical phase II trial involving patients with
oropharyngeal cancer.
Results. An increased percentage of CD4þ cells predicted response to
ICT and suggested improved survival in patients with laryngeal, but not
oropharyngeal, cancer. In the combined group of patients, increased
CD4 levels predicted response to ICT.
Conclusion. These findings demonstrate the potential importance of the
immune system in chemotherapy response and clinical outcome.
Differences in findings between patients with advanced laryngeal and
oropharyngeal cancer may reflect different cellular immunity function in
the patients with human papillomavirus (HPV)-16þ oropharyngeal
cancer.VC 2013 Wiley Periodicals, Inc. Head Neck 36: 9–14, 2014
KEY WORDS: laryngeal cancer, chemotherapy, T lymphocytes,
immunity, oropharyngeal cancer
INTRODUCTION
Induction chemotherapy (ICT) has proven useful for iden-
tifying patients with head and neck squamous cell carci-
noma that is responsive to definitive chemoradiation.1–3
Although this approach has allowed for high rates of
organ preservation and function, its shortcomings include
a high cost, long duration of treatment, and potential tox-
icity, including a 1% to 2% mortality rate, without any
demonstrable overall survival benefit from the ICT itself.4
Identification of new biomarkers that predict whether a
patient’s disease will respond to organ-preserving therapy
could lead to more personalized treatments and the
replacement of ICT with a less costly, less time consum-
ing, and less morbid alternative.
It is well known that both tumor biology and host
immune function play important roles in a cancer’s
response to therapy. Circulating and tumor infiltrating
lymphocyte populations have been studied as indicators
of host immune response in multiple types of cancers and
have shown correlations with response to therapy and
survival.5–7 In advanced oropharyngeal cancer, higher
pretreatment, circulating CD8þ lymphocyte levels were
predictive of response to ICT, and a low ratio of circulat-
ing %CD4þ/%CD8þ lymphocytes was associated with
better survival.8 In an earlier analysis of patients with
advanced laryngeal cancer, we reported that pretreatment
peripheral blood lymphocyte (PBL) levels were not pre-
dictive of response to ICT or survival.9 However, that
report was based on preliminary data from a limited num-
ber of patients enrolled in an ongoing phase II clinical
trial that has since been completed.
A retrospective analysis of the now-completed, prospec-
tive phase II clinical trial was undertaken to determine if
there were correlations between pretreatment PBL levels
and the response to ICT in patients with advanced laryn-
geal cancer. Pretreatment flow-cytometric analyses of
CD3, CD4, CD8, NK, and B lymphocyte percentages and
absolute numbers were available for nearly 80% of
patients (128/163). Functional assays and serum samples
for simultaneous cytokine analyses were not available. To
determine if there were cancer site–specific differences of
importance, we also analyzed comparative data from a
separate phase II clinical trial that investigated the same
ICT approach in patients with advanced oropharyngeal
cancer who received a nearly identical treatment
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protocol.2 To increase the statistical power and explore
significant associations in a larger population with more
varied disease, PBL levels were correlated with response
to ICT in a cohort of patients made by combining those
from the 2 separate trials.
MATERIALS AND METHODS
Patient population
Studied were 163 patients with advanced laryngeal or
oropharyngeal cancer who were enrolled in 2 concurrent
phase II clinical trials that explored the utility of a single
cycle of ICT for selecting patients who would benefit
from subsequent organ-preserving concurrent chemoradia-
tion. The laryngeal cancer phase II clinical trial (UMCC
9520) included 97 patients with pathologically confirmed,
resectable, previously untreated stage III or IV squamous
cell carcinoma of the larynx. All patients were candidates
for a total laryngectomy. The detailed patient characteris-
tics and clinical outcomes were previously reported.1 The
oropharyngeal cancer phase II clinical trial (UMCC 9921)
included 66 patients with pathologically confirmed, re-
sectable, untreated stage III or IV squamous cell carci-
noma of the oropharynx. Details of the clinical outcomes2
and immune parameter correlations8 were previously
reported. The protocols were approved by the Institutional
Review Board at the University of Michigan (Ann Arbor,
MI), and all patients gave documented informed consent.
Treatment protocol
Patients received 1 cycle of ICT consisting of cisplatin
(100 mg/m2/d for 1 day) and fluorouracil (1000 mg/m2/d
for 5 days). Carboplatin (area under the curve ¼ 6) was
used in place of cisplatin for patients with renal insuffi-
ciency or hearing loss. Patients were examined by direct
laryngoscopy before treatment and 3 weeks after ICT to
obtain bidimensional measurements of the primary tumor;
the percentage change of their product was calculated to
quantify tumor regression. In all patients, there was no
question as to whether there was a partial response
(>50% reduction in the bidimensional product) or stable
disease. Among the patients with laryngeal cancer, tumor
regression was 70% among the responders (n ¼ 73)
and 50% among the nonresponders (n ¼ 22). Among
the patients with oropharyngeal cancer, there were 54
responders and 22 nonresponders. Responders to ICT
then underwent definitive, concurrent chemotherapy (cis-
platin 100 mg/m2 on days 1, 22, and 43) and radiotherapy
(70 Gy divided in daily 2-Gy fractions). Nonresponders
to ICT received salvage surgery and radiotherapy. The
full study designs and clinical results were previously
reported.1,2
Lymphocyte subpopulations
Fresh, pretreatment peripheral blood samples were ana-
lyzed at the time of patient enrollment by routine, auto-
mated flow cytometry for WBC, CD3, CD4, CD8, the ra-
tio of CD4 to CD8 cells, and B cells. Percentage and
absolute numbers were obtained. The detailed methods
have been described previously.10 In brief, counts were
obtained using commercially available monoclonal anti-
body reagents by an indirect immunofluorescent tech-
nique and were performed in the clinical laboratories of
the University of Michigan Department of Pathology.
Correlations between patients’ pretreatment peripheral
blood counts and their response to ICT and survival were
determined. Of the 97 patients enrolled in the laryngeal
cancer study, 81 patients (84%) had pretreatment periph-
eral blood samples analyzed. Eight of the 81 patients had
incomplete sets of PBL subset counts. There were no sig-
nificant differences between the subset of patients with
pretreatment peripheral blood counts and those without
with respect to sex, smoking status, disease stage, or
response to ICT (data not shown). The median length of
follow-up was 7.9 years. In the oropharynx trial, PBL
levels were available for 47 patients (71%). Median
length of follow-up in that trial was 6.6 years.
Statistical analysis
Statistical analysis was performed on those participants
of the larynx trial with complete sets of PBL counts.
Absolute counts and percentages were treated as continu-
ous variables. The distributions of each subset were
explored with histograms and quantile–quantile (Q–Q)
plots to assess whether an approximately normal distribu-
tion assumption was reasonable. Initially, all counts and
percentages were assumed to be approximately normal
and differences in response versus nonresponse to therapy
were assessed with a 2-sample t test. Because some sub-
sets showed deviations from normality, we performed
nonparametric Wilcoxon rank-sum tests as well. We
found no difference in the conclusions drawn from the t
test and nonparametric testing. Differences in overall sur-
vival were tested with a log-rank test and plotted using
the Kaplan–Meier method based on 2 differing cutoff val-
ues: (1) the median and (2) the mean plus 2 SEM of the
individual subset levels measured in a population of 40
age-matched normal subjects.10
Additional analyses were performed by combining the
subset values from the larynx trial with those of the oro-
pharynx trial. Tests for significant differences among res-
ponders and nonresponders as well as survival in the
whole group were assessed in the same way as the larynx
trial subjects alone. Differences in effect across trials/dis-
ease sites were then assessed using an interaction term in
our regression modeling. The interaction between disease
site and each peripheral blood subset was tested in logis-
tic regression models for chemotherapy response and Cox
proportional hazards models for overall survival. Data are
presented as mean 6 SEM.
RESULTS
Peripheral blood CD4 counts, response to induction
chemotherapy, and survival in patients with laryngeal
cancer
We investigated whether there was a correlation
between pretreatment PBL counts and the response to
ICT in patients with laryngeal cancer. We found that
CD4 counts, both absolute and percentage, were signifi-
cantly higher in ICT responders compared with nonres-
ponders (see Figure 1). Decreased %CD8 (p ¼ .11),
increased CD4/CD8 ratio (p ¼ .19), and increased %CD3
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cells (p ¼ .13) all trended toward a correlation with
response to ICT. The other lymphocyte counts did not
differ between ICT responders and nonresponders.
We also investigated the relationships between pretreat-
ment PBL levels and the final tumor response, assessed 3
months after the completion of definitive chemoradiation.
We found no significant associations.
When patients were grouped by T or N classification,
we found no significant differences in pretreatment T cell
subset levels except for slightly lower %CD8 cells in
patients with stage IV disease (p ¼ .04).
Because pretreatment peripheral blood CD4 levels were
associated with response to ICT, and induction response
is usually associated with improved survival, we investi-
gated whether CD4 levels were also associated with sur-
vival. Patients were stratified into high and low CD4
groups using the previously identified cutoff values of
CD4 absolute counts and percentages that were deter-
mined by 2 methods: first, using the medians observed
among all patients in the study (899.5 and 50.1%); and
second, using the mean þ 2SEM in 40 normal subjects
(912 and 50%).10 Overall and disease-specific survival
rates were compared between the patients with high and
low CD4 levels using both sets of cutoff values.
We found no significant associations between CD4 levels
and survival (see Figure 2). However, using the median
value as a cutoff produced slightly stronger correlations
than the normal subjects’ mean þ 2SEM, with high CD4
counts trending toward improved overall survival. High
absolute CD4 counts tended to be more strongly associated
with improved survival than high CD4 percentage.
Relationship between peripheral blood lymphocytes and
response to induction chemotherapy in a cohort of
patients with either laryngeal or oropharyngeal cancer
Because it is generally accepted that head and neck
cancer biology differs significantly by tumor site, and
because the laryngeal and oropharyngeal cancer phase II
clinical trials had identical ICT protocols, we had the op-
portunity to determine if there were differing relationships
between pretreatment PBL levels and response to ICT in
a cohort of patients made by combining those from both
of the separate trials (n ¼ 81 in the larynx trial and n ¼
47 in the oropharynx trial). Analyses of the PBL levels
and tumor response to ICT in the oropharyngeal cancer
trial was previously performed.8 We also previously
determined and reported the specific human papillomavi-
rus (HPV) type and copy number in the tumor specimens
from the patients with oropharyngeal trial using real-time,
competitive polymerase chain reaction and matrix-assisted
laser desorption time-of-flight mass spectroscopy.2
We first investigated whether there were differences in
pretreatment PBL levels between the patients with laryn-
geal and oropharyngeal cancer. The only significant dif-
ference we observed was in the pretreatment total WBC,
which was higher in the patients with laryngeal cancer
(9.01 6 0.36 in the larynx trial vs 7.58 6 0.33 in the oro-
pharynx trial; p ¼ .005). When the patients with oropha-
ryngeal cancer were separated into subgroups based on
their tumor HPV-16 status, differences in CD4/CD8 ratio
became significant, with lower ratios in the HPV-16þ
patients, and CD8 cells trending toward a higher percent-
age in HPV-16þ patients with oropharyngeal cancer com-
pared with HPV-16 negative patients with oropharyngeal
cancer (p ¼ .06) (see Figure 3). The CD4/CD8 ratio and
CD8 levels were similar between the laryngeal cancer
and HPV-16þ patients with oropharyngeal cancer.
The groups of patients with laryngeal and oropharyn-
geal cancer were combined to determine if PBL levels
correlated with response to ICT. Increased CD4 levels (%
and absolute) remained significantly associated with a
FIGURE 1. Peripheral blood CD4 counts by response to ICT in
patients with laryngeal cancer. Pretreatment CD4 counts were
significantly higher in patients whose tumors responded to one
cycle of ICT (A) Absolute CD4 counts (p = 0.006). (B) Differential
CD4 percentage (p ¼ 0.04). N ¼ 57 and 19 for responders and
nonresponders, respectively. * ¼ p < 0.05, ** ¼ p < 0.01 by
Student’s t test.
FIGURE 2. Overall survival by peripheral blood CD4 levels in patients with laryngeal cancer. Patients were placed into high and low CD4 groups
using the medians as cut-offs and survival was compared between groups. Overall survival by (A) CD4% (p ¼ 0.36) and (B) CD4 count (p ¼ 0.15).
N ¼ 39 per group. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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response to ICT (see Figure 4). A trend was also noted
toward increased CD3 counts being associated with
response to ICT (p ¼ .12). Notably, CD8 levels and
CD4/CD8 ratio were not significantly associated with tu-
mor response to ICT.
Predictive potential of peripheral blood lymphocytes and
response to induction chemotherapy by statistical
modeling
We used a logistic regression interaction model to
explore the potential use of PBL counts to predict
response to ICT in patients with either laryngeal and oro-
phayngeal cancer. PBL counts were log-transformed to
improve normality. Patients from the 2 trials were pooled
to develop the model. The model was then applied to the
same patients, taking into account their disease site, to
examine whether PBL counts had different predictive pat-
terns between sites.
There were interesting differences in the predictive
potential for CD4 and CD8 counts between patients with
laryngeal and oropharyngeal cancer (see Figure 5). In
Figure 5, the predictive association of a given PBL level
with response to ICT is represented by the slope of a
line, with a steeper slope indicating a stronger predictive
relationship. CD4 levels in the patients with laryngeal
cancer showed a strong, positive predictive potential
(meaning higher CD4 values predicted a higher probabil-
ity of response to ICT), consistent with the significant
correlation between CD4 levels and the response to ICT
we observed. In the patients with oropharyngeal cancer, a
significant correlation between CD4 levels and the
response to ICT was not observed using this model; how-
ever, a positive predictive potential was evident, although
not as strong as in the larynx. These data suggest that if
the oropharynx trial included more patients, a correlation
between high CD4 counts and response to ICT may have
reached significance. For CD8 levels, the model shows a
clear difference in the predictive potential between the
patients with laryngeal and oropharyngeal cancer. In the
oropharynx, where HPV-16 status is very important, there
is a strong, positive predictive potential for CD8 counts,
whereas in the larynx there is almost no predictive poten-
tial (indicated by a line slope of nearly 0). Finally, CD3
counts showed a strong positive predictive potential in
both sites (data not shown).
DISCUSSION
A major finding of this study was that high pretreat-
ment peripheral blood CD4 levels (both % and absolute)
predicted a clinical tumor response to a single cycle of
ICT, and trended toward predicting improved survival in
patients with advanced laryngeal cancer. Furthermore,
low CD8, high CD4/CD8 ratio, and high CD3 levels
showed trends toward an association with tumor response
to ICT. These preliminary findings, in a small retrospec-
tive cohort, provide additional evidence that systemic
host immune reactivity is involved in the clinical
response to cytotoxic chemotherapy. These results are in
contrast to our previous, work-in-progress report that
found no associations between pretreatment circulating
lymphocyte levels and the response to ICT in patients
with laryngeal cancer.9 The difference in findings
between these reports was likely due to the increased
number of patients that were included in the current anal-
ysis, which was needed to reach sufficient power to
detect the observed difference in CD4 levels between the
ICT responders and nonresponders. These results are im-
portant because they suggest that PBL levels could be
useful in identifying patients with laryngeal cancers that
would be responsive to organ-preserving therapy. Further-
more, PBL counts reflect one aspect of cellular immune
reactivity, which may be important in a patient’s overall
prognosis.
CD4þ lymphocytes are known to exhibit variable roles
in tumor immunity. CD4þ Th cells act beneficially to
facilitate tumor eradication, whereas regulatory T cells
(Tregs), which are largely CD4þCD25þ, are potent
inhibitors of the antitumor response.11 This study extends
the evidence for the predictive utility of pretreatment,
FIGURE 3. Comparison of PBL levels between laryngeal and oropharyngeal cancer. Patients with oropharyngeal cancer were separated into
subgroups based on their HPV-16 status. (A) WBC counts (p = 0.001), (B) CD4/CD8 ratio (p ¼ 0.02), (C) CD8 percentage (p ¼ 0.06). N ¼ 78-83 for
larynx; 11 for OP, HPV(-); and 19-22 for OP, HPV(+). * ¼ p < 0.05, *** ¼ p < 0.001 by log-rank test.
FIGURE 4. PBL levels by response to ICT, laryngeal and oropharyngeal
cancer cohorts combined. (A) CD4 absolute counts (p ¼ 0.02) and (B)
CD4 percentage (p ¼ 0.02). N ¼ 89-91 in responders and 22-24 in
nonresponders. * ¼ p < 0.05 by Student’s t test.
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circulating CD4þ cell levels to potentially identify
patients for organ-preserving treatment. It remains to be
determined if the increased levels of CD4 cells in res-
ponders are due to the expansion of Th or Treg cells. The
mechanism by which circulating CD4þ lymphocytes are
associated with tumor response to chemotherapy is not
clear. At the time that this study was conducted, the role
of Tregs in cancer was not known, so we did not analyze
for the different subsets of CD4þ lymphocytes. Presum-
ably, it is a greater number of Th cells, and not Treg
cells, in the pretreatment peripheral blood that is responsi-
ble for the correlation with response to therapy. However,
further prospective investigation into the types and activ-
ities of pretreatment, circulating CD4þ cells, and tumor
infiltrating lymphocytes in laryngeal cancer is needed.
Tumor biology also plays a critical role in response to
therapy. The results of this study show striking differen-
ces in response to therapy between the tumor sites. The
difference in findings between the laryngeal and oropha-
ryngeal cancer trials suggests that, immunologically, these
tumors likely differ by biological and genetic factors, in
addition to site, and that these may be related to differing
immune responses. A closely related confirmation of this
is seen in patients with oropharyngeal cancer, where tu-
mor HPV-16 status was significantly associated with
altered T lymphocyte levels and response to therapy.8
The current results in laryngeal cancer also differ from a
similar study that investigated the predictive utility of
pretreatment, circulating lymphocytes in patients with
HPV-16–related oropharyngeal cancer.8 In that study, a
higher %CD8 cells and a low CD4/CD8 ratio were found
to predict response to ICT and improved survival; in con-
trast to our findings in patients with laryngeal cancer,
where mean CD8 percentages were similar to those in
HPV-16þ patients with oropharyngeal cancer but were
not related to chemotherapy response.
Pretreatment WBC and CD4/CD8 ratios differed among
the patients grouped and analyzed by laryngeal, HPV-
16þ oropharyngeal, and HPV-16- oropharyngeal cancer
types. The total WBC counts were lower in patients with
HPV-16þ oropharyngeal cancer, which may be due in
part to lower rates of smoking in this group, in that many
of these patients were nonsmokers and smoking is known
to increase WBC counts.12 The CD4/CD8 ratio was
higher and the CD8 counts trended lower in patients with
HPV-16 oropharyngeal cancer, which had the worst
response to therapy among the groups studied. The statis-
tical prediction model was consistent with the previously
demonstrated correlation between high CD8 levels and a
response to ICT in the oropharynx, and additionally, it
showed no such pattern in the larynx, further illustrating
the potentially important differences in host–tumor inter-
actions between patients with tumors arising at these
sites.
Another interesting finding was that high CD4 cell lev-
els were predictive of a response to ICT in the combined
group of laryngeal and oropharyngeal trial patients. The
correlation between high CD4 levels and response to ther-
apy was less strong in the combined group than in the lar-
ynx group alone, suggesting that this association may be
driven largely by the larynx group, although the predic-
tion model showed that this association might also be evi-
dent in the oropharynx if a greater number of patients
were studied. High CD3 levels became more strongly cor-
related with a response to therapy in the combined group
than in the larynx patient group alone, but it did not reach
statistical significance. The prediction model strongly sup-
ported this finding.
A major strength of this study was the prospective clin-
ical trial design with uniform treatment regimens, a rela-
tively large number of patients, and long follow-up. Addi-
tionally, the flow-cytometric analyses were performed by
experts in a clinical pathology laboratory on fresh periph-
eral blood samples. Unfortunately, only retrospective cor-
relations with immune markers were possible, and
although we assume that T lymphocyte numbers reflect
cellular immune system homeostasis, they do not provide
information on immunological function. They also do not
allow for conclusions about the potential mechanisms re-
sponsible for the correlation between PBLs and response
to therapy. Levels of PBLs also do not necessarily reflect
the immune response in the tumor microenvironment.
However, they do begin to provide additional evidence
that the balance among T-cell subsets, which are influ-
enced by cytokines and regulatory T cells, is important in
patients with head and neck cancer. Consistent with this
FIGURE 5. Predictive potential of PBLs by statistical modeling.
Graphs show estimated probability of response to ICT as a
function of (A) CD4 and (B) CD8 absolute counts based on a
logistic regression interaction model. Increased slope of a line
indicates a stronger predictive relationship between a PBL and
response to ICT. Cell counts were log-transformed to improve
normality. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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notion, a functioning immune system has recently been
related to effective chemotherapy.13,14 Future investiga-
tions should focus on the functional interaction between
tumor genetics, tumor biology, and the immune system,
including both PBL and tumor infiltrating lymphocytes,
prior to and over the course of treatment.
CONCLUSIONS
In this study, we found that, in patients with advanced
laryngeal cancer, increased pretreatment peripheral blood
CD4 levels were highly predictive of a response to ICT
and demonstrated a trend toward improved overall sur-
vival. In a combined group of patients with laryngeal or
oropharyngeal cancer, response to ICT was also predicted
by increased CD4 levels, but statistical modeling indi-
cated that the predictive relationship of lymphocyte sub-
sets and tumor response differed significantly by the site
of tumor origin. These differences may be explained in
part by the differing tumor biology of HPV-16–related
cancer.
In an age of multidisciplinary, multimodal therapy,
these observations add to previous evidence that immune
parameters may be useful for identifying subsets of
patients with disease that will respond to organ-preserv-
ing therapy. A better understanding of host immune func-
tion and tumor biology should allow for the development
of less morbid, more personalized, less costly, and less
time-consuming methods of selecting the optimal therapy
for each individual patient.
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